Hengrui is the first to review the variety whose sales have soared by 300%

Since the first review, the tripartite game about products, markets, and prices has begun.

According to the data, Paricalcitol injection was first developed and marketed by AbbVie, and was approved for import in 2013.

Paricalcitol injection was developed by AbbVie and was approved by the FDA on April 17, 1998.

Paricalcitol is the latest generation of selective vitamin D receptor agonist, combined with vitamin D receptor to effectively reduce parathyroid hormone (PTH), used for the treatment of secondary hemodialysis patients with chronic renal failure Hyperparathyroidism.

Among them, paricalcitol, as a drug of choice for the treatment of hyperparathyroidism caused by dialysis in chronic kidney disease, has been widely used in European and American countries.

2.

According to data from Menet.

On the official website of the State Food and Drug Administration, using "Paricalcitol" as a keyword search, there are currently four domestic manufacturers, namely Shanxi Weiqida Guangming Pharmaceutical, Chengdu Yuandong Biopharmaceutical, Beijing Tide Pharmaceutical Co.

In accordance with relevant policies, the drug varieties that have passed the consistency evaluation shall be announced by the State Food and Drug Administration to the public, and appropriate support shall be provided in the payment of medical insurance.

In the past, many provinces would also adopt the policy of "directly linking to the Internet and purchasing from the hospital" for consistency evaluation products.

To a certain extent, although the target of the consistency evaluation is mass purchase, the first company that has passed the evaluation will enjoy a longer window dividend period before the product is collected.

3.

Regarding the variety of Paricalcitol injection, the original research drug has gradually withdrawn from the battlefield: from the exclusive market in 2017, it fell to 66% in 2018, and only less than 20% of the market share remained in 2020.
What followed was a battle of reviews among domestic pharmaceutical companies.

According to data from Meinenet, the supplementary application for consistency evaluation of Shanxi Weiqida Guangming Pharmaceutical and Chengdu Yuandong Biopharmaceutical is under review and approval; Suzhou Netac Biotech|Hebei Kaiwei Pharmaceutical applies for generic 4 types of production, which will be considered after approval The same comment.

Many companies are catching up, and it is still unknown how long Hengrui's first review window can last.

At present, dozens of provinces have issued relevant policies: For 3 products that have passed the consistency evaluation, the online procurement qualification of the products that have not passed the consistency evaluation is suspended; the production of the same variety of drugs through the quality and efficacy consistency evaluation of generic drugs If there are more than 3 enterprises, and products that have not passed the consistency evaluation, and have entered the provincial drug centralized procurement platform for online transactions, in principle, the online transaction qualifications are suspended.
Those who have not entered the provincial centralized drug procurement platform for online transactions will not be included in the provincial centralized drug procurement for the time being.

For example, on May 21, the Hainan Provincial Public Resources Trading Service Center issued a notice that some of the unselected national collections that have not passed the consistency evaluation plan to withdraw from the network, involving 63 drugs from 45 pharmaceutical companies.
The notice clearly stated that, in accordance with the requirements of the Hainan Provincial Medical Security Bureau for the implementation of the national organization of centralized drug procurement, “If there are more than three drugs that have passed the quality and efficacy consistency evaluation on the Internet in our province (excluding original research drugs and reference preparations), the Drugs that have passed the consistency evaluation of quality and efficacy will be removed from the network.
After verification, the list of drugs to be removed from the network is now publicized, and the publicity period is until 5 pm on May 25, 2021.

When two products have been over-reviewed and an original research drug is added, the conditions for centralized procurement are virtually met-over-reviewed generic drugs must make a choice in the "zero-sum game" of occupying the mainstream market and losing the market, and through consensus Sexual evaluation is still the lowest price with peer PK; and for original research drugs, such as AbbVie’s Paricalcitol injection, it has already lost most of the market.
Collective procurement or a good opportunity to regain the market without blood ——Therefore, the original research drug also has the motivation to cut prices sharply to grab the market.

When three companies have been reviewed, it means that the elimination mechanism has been opened, and products that have not been reviewed will be gradually kicked out of the market.
Starting from the first review, the tripartite game of products, markets, and prices has begun.